IDXX
NasdaqIDEXX LABORATORIES INC /DE
Basic Materials · In Vitro & In Vivo Diagnostic Substances
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$3.2B
2021
$3.4B
2022
$3.7B
2023
$3.9B
2024
$4.3B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$4.3B
Net Income$1.1B
Gross Profit$2.7B
Oper Income$1.4B
EPS (dil)$13.08
Rev/sh$54.56
FCF/sh$13.40
Book/sh$20.35
Gross M61.8%
Oper M31.6%
Profit M24.6%
FCF M24.6%
ROE66.0%
ROA31.6%
ROIC55.8%
R&D/Rev5.8%
Rev Y/Y10.4%
Rev 3Y CAGR8.5%
EPS Y/Y22.6%
EPS 3Y CAGR17.7%
FCF 3Y CAGR38.9%
Payout—
Div/sh—
Shs Chg Y/Y-2.7%
Current Ratio1.23
Quick Ratio0.90
Debt/Eq0.33
Int Coverage35.0×
Net Debt$344.9M
Total Debt$525.0M
Cash & Eq$180.1M
Total Assets$3.4B
Oper CF$1.2B
Capex$124.7M
Free CF$1.1B
Buybacks$1.2B
Equity$1.6B
Liabilities$1.7B
Shs Outstand0.08B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $3.4B | $3.7B | $3.9B | $4.3B |
| Gross Profit | $1.9B | $2.0B | $2.2B | $2.4B | $2.7B |
| Operating Income | $932.0M | $898.8M | $1.1B | $1.1B | $1.4B |
| Net Income | $744.8M | $679.1M | $845.0M | $887.9M | $1.1B |
| Diluted EPS | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| Operating Cash Flow | $755.5M | $543.0M | $906.5M | $929.0M | $1.2B |
| Free Cash Flow | $636.0M | $394.1M | $772.9M | $808.1M | $1.1B |
COMMUNITY · $IDXX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.